Company news
Imugene Ltd news in 2020
Imugene Ltd's news releases, calls and decks from 2020, newest first.
Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial
December 16, 2020
Imugene Receives $4.82 million R&D Tax Incentive
December 10, 2020
Imugene First Patient Dosed in PD1-VAXX Clinical Trial
November 30, 2020
Imugene HER Vaxx shows positive Overall Survival in trial
November 22, 2020
Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
November 1, 2020
Imugene Immunotherapy Combination Patent Granted in US
October 1, 2020
Imugene Secures $5.7 million Option Underwriting Agreement
September 8, 2020
Imugene Receives PD1-VAXX Ethics Trial Approval in USA
September 3, 2020
Appendix 4E & Annual Report to shareholders
August 31, 2020
Imugene Receives Third PD1-VAXX Ethics Trial Approval
August 20, 2020
Imugene Receives Clinical Guidance from US FDA for Vaxinia
August 5, 2020
Imugene Receives Second PD1-VAXX Ethics Trial Approval
July 16, 2020
Imugene Receives Ethics Approval to Start PD1-VAXX Trial
July 13, 2020
Imugene HER-Vaxx Phase 2 Clinical Update
May 3, 2020
Imugene PD1-Vaxx Immunotherapy Update
January 27, 2020
Imugene HER-Vaxx Immunotherapy Patent Granted in US
January 13, 2020
Decks in 2020
- Shareholder Meeting (November 2020)
Shareholder meeting · 14 slides · Nov 24, 2020
- Investor Presentation (November 2020)
Investor deck · 31 slides · Nov 24, 2020